



Featured Stocks in January's Most Attractive/Most Dangerous Model Portfolios

Recap from December's Picks

Our Most Attractive Stocks (+3.1%) underperformed the S&P 500 (+3.9%) from December 4, 2019 through January 3, 2020. The best performing large cap stock gained 9% and the best performing small cap stock was up 22%. Overall, 16 out of the 40 Most Attractive stocks outperformed the S&P 500.

Our Most Dangerous Stocks (+3.3%) outperformed the S&P 500 (+3.9%) as a short portfolio from December 4, 2019 through January 3, 2020. The best performing large cap stock fell by 4% and the best performing small cap stock fell by 11%. Overall, 27 out of the 40 Most Dangerous stocks outperformed the S&P 500 as shorts.

Get the best fundamental research

Only our research utilizes the superior data and earnings adjustments featured by the HBS & MIT Sloan paper, "[Core Earnings: New Data and Evidence](#)." The successes of these model portfolios highlight the value of our machine learning and AI [Robo-Analyst technology](#)¹, which helps clients fulfill the [fiduciary duty of care](#) and make smarter investments².

10 new stocks make our Most Attractive list this month, and four new stocks fall onto the Most Dangerous list this month. January's Most Attractive and Most Dangerous stocks were made available to members on January 7, 2020.

Our Most Attractive stocks have high and rising returns on invested capital ([ROIC](#)) and low [price to economic book value ratios](#). Most Dangerous stocks have [misleading earnings](#) and long [growth appreciation periods](#) implied by their market valuations.

Most Attractive Stocks Feature for January: Molina Healthcare, Inc. (MOH: \$143/share)

Molina Healthcare, Inc. (MOH), is the featured stock from January's [Most Attractive Stocks Model Portfolio](#).


Over the past decade, MOH has grown after-tax profit ([NOPAT](#)) by 36% compounded annually. The firm's trailing twelve month (TTM) NOPAT is up 29% over the prior TTM period. Its NOPAT margin has averaged 2% over the past decade and is up to 5% over the TTM period. This boost in profitability is a direct result of lower medical care costs and the 2018 sale of underperforming businesses. MOH also currently earns a top-quintile return on invested capital ([ROIC](#)) of 22%.

¹ Harvard Business School features the powerful impact of our research automation technology in the case [New Constructs: Disrupting Fundamental Analysis with Robo-Analysts](#).

² This [paper](#) compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up.



Figure 1: MOH's Revenue & NOPAT Since 2008



Sources: New Constructs, LLC and company filings

MOH's Valuation Offers Upside Potential

At its current price of \$132/share, MOH has a price-to-economic book value (PEBV) ratio of 0.7. This ratio means the market expects MOH's NOPAT to permanently decline by 30%. This expectation seems overly pessimistic for a firm that has grown NOPAT by 36% compounded annually over the past decade.

If MOH can maintain its 2018 NOPAT margin of 4% (compared to 5% TTM) and grow NOPAT by 6% compounded annually (less than half the NOPAT CAGR of 13% from 2009 to 2017) for the next decade, the stock is worth \$295/share today – a 123% upside. [See the math behind this reverse DCF scenario.](#)

Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)

As investors [focus more](#) on fundamental research, research automation technology is needed to analyze all the critical financial [details in financial filings](#) as shown in the Harvard Business School and MIT Sloan paper, "[Core Earnings: New Data and Evidence](#)".

Below are specifics on the adjustments we make based on Robo-Analyst findings in Molina Healthcare's 2018 10-K:

Income Statement: we made \$280 million of adjustments, with a net effect of removing \$120 million in [non-operating expenses](#) (1% of revenue). You can see all the adjustments made to MOH's income statement [here](#).

Balance Sheet: we made \$1.2 billion of adjustments to calculate invested capital with a net increase of \$958 million. One of the largest adjustments was \$456 million due to asset [write-downs](#). This adjustment represented 16% of reported net assets. You can see all the adjustments made to MOH's balance sheet [here](#).

Valuation: we made \$1.6 billion of adjustments with a net effect of decreasing shareholder value by \$1.6 billion. There were no adjustments that increased shareholder value. The most notable adjustment to shareholder value was \$129 million in [off-balance-sheet operating leases](#). This adjustment represents 1% of MOH's market cap. See all adjustments to MOH's valuation [here](#).

Most Dangerous Stocks Feature: Linde, PLC (LIN: \$212/share)


Linde, PLC (LIN), is the featured stock from January's [Most Dangerous Stocks Model Portfolio](#).

We previously put LIN in the Danger Zone on [October 28, 2019](#). The stock has slightly underperformed the market (+8% vs S&P +9%) and remains overvalued.



LIN's [economic earnings](#) declined from \$955 million in 2014 to -\$2.8 billion TTM, per Figure 2. LIN's NOPAT margin has fallen from 17% in 2014 to 7% TTM while ROIC fell from 10% to 2% over the same time.

Figure 2: LIN's Economic Earnings Since 2014



Sources: New Constructs, LLC and company filings

LIN Provides Poor Risk/Reward

Despite its deteriorating fundamentals, LIN is still priced for significant profit growth and is overvalued.

To justify its current price of \$210/share, LIN must maintain 2018 NOPAT margins of 14% (compared to 7% TTM) and grow NOPAT by 12% compounded annually for 15 years. [See the math behind this reverse DCF scenario](#). This expectation seems overly optimistic given that LIN's NOPAT has fallen by 3% compounded annually since 2014.

Even if we assume LIN can achieve a 14% NOPAT margin and grow NOPAT by 10% compounded annually for the next decade, the stock is worth only \$106/share, a 50% downside. [See the math behind this reverse DCF scenario](#).

Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)

As investors [focus more](#) on fundamental research, research automation technology is needed to analyze all the critical financial [details in financial filings](#) as shown in the Harvard Business School and MIT Sloan paper, "[Core Earnings: New Data and Evidence](#)".

Below are specifics on the adjustments we make based on Robo-Analyst findings in Linde, PLC's 2018 10-K:

Income Statement: we made \$4.5 billion of adjustments, with a net effect of removing \$2.4 billion in [non-operating income](#) (16% of revenue). You can see all the adjustments made to LIN's income statement [here](#).

Balance Sheet: we made \$72.4 billion of adjustments to calculate invested capital with a net decrease of \$49 billion. One of the largest adjustments was \$50.4 billion for [midyear acquisitions](#). This adjustment represented 63% of reported net assets. You can see all the adjustments made to LIN's balance sheet [here](#).

Valuation: we made \$27.9 billion of adjustments with a net effect of decreasing shareholder value by \$24.3 billion. Apart from \$14.2 billion in [total debt](#), the largest adjustment to shareholder value was \$6.9 billion in [net deferred tax liability](#). This adjustment represents 6% of LIN's market cap. See all adjustments to LIN's valuation [here](#).

This article originally published on [January 16, 2020](#).

Disclosure: David Trainer, Kyle Guske II, and Matt Shuler receive no compensation to write about any specific stock, style, or theme.



Follow us on [Twitter](#), [Facebook](#), [LinkedIn](#), and [StockTwits](#) for real-time alerts on all our research.

Footnotes adjustments matter. We are the ONLY source.

We provide ratings, models, reports & screeners on U.S. 3,000 stocks, 700 ETFs and 7,000 mutual funds.

HBS & MIT Sloan research reveals that:

- **Markets are inefficiently assessing earnings because no one reads the footnotes.**
- **Our technology brings the material footnotes data to market for the first time ever.**

Combining human expertise with NLP/ML/AI technologies ([featured by Harvard Business School](#)), we shine a light in the dark corners (e.g. footnotes) of hundreds of thousands of financial filings to unearth critical details.

The HBS & MIT Sloan paper, [Core Earnings: New Data and Evidence](#), shows how our superior data drives uniquely comprehensive and independent debt and equity research.

This [paper](#) compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up.

Quotes from HBS & MIT Sloan professors on our research:

Get better research:

“...the NC dataset provides a novel opportunity to study the properties of non-operating items disclosed in 10-Ks, and to examine the extent to which the market impounds their implications.” – page 20

Pick better stocks:

“Trading strategies that exploit cross-sectional differences in firms’ transitory earnings produce abnormal returns of 7-to-10% per year.” – Abstract

Avoid losses from using other firms’ data:

“...many of the income-statement-relevant quantitative disclosures collected by NC do not appear to be easily identifiable in Compustat...” – page 14

Build better models:

“Core Earnings [calculated using New Constructs’ novel dataset] provides predictive power for various measures of one-year-ahead performance...that is incremental to their current-period counterparts.” – page 4

Exploit market inefficiencies:

“These results ... suggest that the adjustments made by analysts and Compustat to better capture core earnings are incomplete. Moreover, the non-core items identified by NC produce a measure of core earnings that is incremental to alternative measures of operating performance in predicting an array of future income measures.” – page 26

Fulfill fiduciary duties:

“An appropriate measure of accounting performance for purposes of forecasting future performance requires detailed analysis of all quantitative performance disclosures detailed in the annual report, including those reported only in the footnotes and in the MD&A.” – page 33-34



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.